Travere Therapeutics Q4 Earnings Call Highlights

Heerma attributed fourth-quarter momentum to several factors, including FILSPARI’s differentiated profile as a once-daily oral, non-immunosuppressive therapy; simplified REMS monitoring requirements ; and the publication of KDIGO guidelines . He also said adoption is increasing in IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guideline direction toward earlier intervention and lower targets. When asked to quantify what proportion of fourth-quarter patient start forms came f ...